This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rizvi, A. A. Articles by Kallal, J. E. Search for Related Content PubMed PubMed Citation Articles by Rizvi, A. A. Articles by Kallal, J. E. Social Bookmarking                         What's this?

Capecitabine-Induced Coronary Vasospasm

A Case Report

Divisions of Cardiology, Department of Medicine, Hartford Hospital, Hartford, CT.

Peter Schauer, MD

Divisions of Hematology/Oncology, Department of Medicine, Hartford Hospital, Hartford, CT.

Dariush Owlia, MD

Divisions of Cardiology, Department of Medicine, Hartford Hospital, Hartford, CT.

James E. Kallal, MD

Divisions of Cardiology, Department of Medicine, Hartford Hospital, Hartford, CT.

The authors report the case of a 70-year-old man with metastatic colon cancer and no known history of coronary disease or major risk factors who developed coronary vasospasm after the initiation of capecitabine (Xeloda®). Although coronary vasospasm has been associated with another older fluoropyrimidine compound, 5-fluorouracil, this is the first reported occurrence with this relatively newer cancer drug.

Angiology, Vol. 55, No. 1, 93-97 (2004)
DOI: 10.1177/000331970405500114


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?